JD Bioscience Co., Ltd. (CEO Ahn Jin-hee) announced that it will participate in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
JD Bioscience is a pharmaceutical company established in 2017 led by medicinal chemists and physician researchers, and is developing new compounds that can accurately inhibit or activate disease targets, which are the core of new drug development. Major indications include non-alcoholic fatty liver, inflammatory enteritis, and colorectal cancer caused by metabolic abnormalities, and other treatments are being developed with a focus on diseases with high unmet medical needs.
The company’s main pipeline is a non-alcoholic fatty liver treatment with a mechanism that inhibits serotonin signaling outside the central nervous system, and is currently conducting clinical trials 1a/b in Australia. The second pipeline suppresses inflammation by regulating mitochondrial function in immune cells. It is a therapeutic agent for inflammatory diseases.
An official from JD Bioscience said, “Through this exhibition, we intend to transfer the rights after the completion of phase 1 clinical trial of a drug candidate for non-alcoholic fatty liver treatment currently in clinical trials, or to discover companies that will conduct phase 2 clinical trials together in the United States.” In addition, the compound under development shows a mechanism of action (MOA) that directly inhibits hepatic fibrosis, so we are interested in co-administration with drugs that have liver fat accumulation.”
‘GM-60106, A novel drug candidate for Nonalcoholic steatohepatitis’ (NASH) is a first-in-class (innovative new drug) drug candidate with a new MOA that can effectively inhibit liver fibrosis. It inhibits liver fibrosis and is designed not to penetrate the brain, so it can be safely taken orally without side effects related to the central nervous system. A phase 1 clinical trial is currently underway in Australia and is scheduled to end at the end of this year.
The company said, “Currently, we are focusing on developing treatments that control new disease targets. To this end, when a new disease-related protein (target) is discovered in the process of analyzing patient samples by clinical doctors at university hospitals, a large amount of regulator (inhibitor or enhancer) compound is synthesized based on medical and chemical know-how, and then the optimal substance is selected. “We started developing new drugs based on the results of many years of basic research that the target protein (HTR2A), which is often found in patients suffering from NASH, can play a key role in the treatment of NASH,” he said. introduced.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.